ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announces a progressive year of product innovation and talent acquisition. The company will virtually display its latest advancements in image enhancement as well as introduce new key staff to attendees of RSNA 2020.
ContextVision’s third quarter sees a recovery in sales and market entry in digital pathology is on track
ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its third quarter.
Today ContextVision presented the company at a shareholder webinar arranged by Norne and ContextVision. CEO Fredrik Palm gave an update of the company’s development and shared the company’s future direction. Please find a PDF-version of the presentation attached. The presentation will also be published on the company's website.
We are pleased to invite you to a presentation of Contextvision AB and its 2nd quarter and half year 2020 figures and give an update on the company’s development and ongoing projects. The presentation will be held as an online webinar on Thursday, September 24th at 11:30.
Ola Lindblad, VP Medical Imgaing of ContextVision, has on August 27, 2020 purchased 1,800 shares in ContextVision AB at an average price of NOK 22.37 per share. After the transaction, Mr Lindblad holds a total of 6,300 shares in ContextVision AB.
STOCKHOLM – August 17, 2020 – Fredrik Palm, CEO of ContextVision, has on August 17, 2020 purchased 200 shares in ContextVision AB at an average price of NOK 245 per share. After the transaction, Mr Palm holds a total of 2,820 shares in ContextVision AB. For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 […]
STOCKHOLM – Aug 13, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announces key information relating to the share spilt after a decision by the Board of Directors as of August 12th 2020. Reference is made to the extraordinary general meeting of ContextVision, held on August 5th, […]
ContextVision today reports a progressive second quarter. INIFY® Prostate Screening – the company’s first decision support tool in a planned digital pathology portfolio – was granted CE-mark status, paving the way for a strong entry into the fast-growing digital pathology market. In addition, the company continues to spearhead the image enhancement market with its new next-generation ultrasound product, Rivent®.
On the 5th of August 2020, ContextVision held an Extraordinary General Meeting in Stockholm. The Board’s proposal for adoption of new articles of association was approved The Board’s proposal for decision on the share split of the company’s share was approved No other matters were processed at the meeting. For further information, please contact:Ann-Charlotte Linderoth […]
ContextVision today announced that its first digital pathology product in a planned portfolio has been granted CE mark status. This means that INIFY® Prostate Screening is now available for routine clinical use within the European Union.